Teaser text

The AI-empowered biomedicine laboratory develops cutting-edge innovative AI and machine-learning methodologies to integrate and interpret large-scale molecular and clinical data to promote personalised medicine and precision therapy.

Body Text

Competitive advantage

  • Multidisciplinary expertise and cross-faculty collaborations
  • Developing advanced machine-learning methods and deep-learning models that leverage large omics data

Impact

  • Improving translational genomics and personalised medicine
  • Facilitating tailored treatment and precision therapy
  • Reducing the cost and timeframe of drug development
  • Reducing the risk of type 2 diabetes
  • Developing downloadable/online toolkits reusable in different clinical settings

Successful outcomes

  • Discovery of circulating microRNA markers of colorectal cancer prognosis
  • Identification of diagnostic non-coding RNAs in ovarian tumour microenvironment associated with metastasis
  • Identification of exosomal microRNA biomarkers for non-invasive glioblastoma diagnosis
  • ExomiR signatures of disease status in multiple sclerosis
  • Network-based drug repositioning led to identification of less-toxic cancer treatment drugs
  • Prediction of functional noncoding variants in human brain genome (in progress)
  • Comprehensive databases on mammalian cellular interactions
  • Development of computational tools and software for biomarker discovery and drug repurposing

Capabilities and facilities

  • High-Performance Computing (HPC) resources for model development
  • Access to Australia‚Äôs largest genomics facilities with state-of-the-art next-generation sequencing technologies
  • Highly multidisciplinary research network enabling translation of the research outcomes

Our partners

  • Nutromics Pty Ltd
  • BCAL Diagnostics
  • Royal Prince Alfred Hospital